In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Cole Werble

Washington, DC
Cole Werble is the former owner and editorial director of FDC Reports, Inc., the publisher of The Pink Sheet, The Gray Sheet, and other leading news publications for the health care industry. He has more than 35 years of experience analyzing business critical developments affecting the biopharma sector and developing world class information products for the sector.

Latest From Cole Werble

Vaccines After COVID: Catch-Up Watch Under Way

There has been a dramatic drop-off in routine immunization rates in the US and around the world amid the COVID-19 outbreak. The catch-up effort may complicate the pandemic response efforts.

Vaccines Commercial

Turning Vaccine Priority Upside Down: Applying H1N1 Lessons To COVID-19

A successful COVID-19 vaccine candidate will create a critical challenge: who receives the first doses of what is bound to be a constrained supply? Vaccine developers see useful lessons from the 2009 H1N1 outbreak – but a very different priority order.

Vaccines Distribution

COVID-19 Vaccines: A Dose Of Caution From Merck

The global COVID-19 pandemic is prompting an unprecedented effort to develop a vaccine in record-breaking time. But there may be pitfalls in letting optimism run too far ahead of the realities of vaccine development.

Coronavirus COVID-19 Vaccines

Trump Halt To US Funding For WHO: Making Global Health, Government Organization Potent Issues

Selling government efficiency as a campaign issue has not been an easy task for Democrats. COVID-19 – and especially support for international responses – may present a new opportunity.

Coronavirus COVID-19 Politics

COVID-19 Trial Changes Are "Propulsive Force" For Digital Adoption

Robert Califf, a former FDA commissioner turned Verily Life Sciences exec, is just one of the voice predicting a long-term impact on clinical trial processes from the COVID-19 outbreak.

Coronavirus COVID-19 Digital Health

Digital Doublespeak: The Language Barrier When Tech Companies Meet Regulators

A US National Academies meeting on digital health technology showcased the communication gap between regulators and tech developers when it comes to important concepts like “digital biomarkers.”

Digital Health Drug Approval Standards
See All